![From injections to pills: FDA approves first oral GLP-1 for type 2 diabetes - Pharmaceutical Technology From injections to pills: FDA approves first oral GLP-1 for type 2 diabetes - Pharmaceutical Technology](https://www.pharmaceutical-technology.com/wp-content/uploads/sites/24/2019/10/diabetes-2.jpg)
From injections to pills: FDA approves first oral GLP-1 for type 2 diabetes - Pharmaceutical Technology
![New anti-obesity drugs are closing gap between dieting and bariatric surgery | Diet and Nutrition | Prevention | UT Southwestern Medical Center New anti-obesity drugs are closing gap between dieting and bariatric surgery | Diet and Nutrition | Prevention | UT Southwestern Medical Center](https://s3-us-west-2.amazonaws.com/utsw-patientcare-web-production/original_images/Anti-obesity_graphic_500.jpg)
New anti-obesity drugs are closing gap between dieting and bariatric surgery | Diet and Nutrition | Prevention | UT Southwestern Medical Center
![IJMS | Free Full-Text | Oral Semaglutide, the First Ingestible Glucagon-Like Peptide-1 Receptor Agonist: Could It Be a Magic Bullet for Type 2 Diabetes? IJMS | Free Full-Text | Oral Semaglutide, the First Ingestible Glucagon-Like Peptide-1 Receptor Agonist: Could It Be a Magic Bullet for Type 2 Diabetes?](https://pub.mdpi-res.com/ijms/ijms-22-09936/article_deploy/html/images/ijms-22-09936-g001.png?1631693374)
IJMS | Free Full-Text | Oral Semaglutide, the First Ingestible Glucagon-Like Peptide-1 Receptor Agonist: Could It Be a Magic Bullet for Type 2 Diabetes?
![GLP-1 Receptor Agonists for the Reduction of Atherosclerotic Cardiovascular Risk in Patients With Type 2 Diabetes | Circulation GLP-1 Receptor Agonists for the Reduction of Atherosclerotic Cardiovascular Risk in Patients With Type 2 Diabetes | Circulation](https://www.ahajournals.org/cms/asset/96c991b5-3fb8-4715-93b4-a5de1065b3fc/circulationaha.122.059595.fig01.jpg)